Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations
- Registration Number
- NCT00547287
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
Study to determine if men from around the world prefer sildenafil to tadalafil.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 2760
Inclusion Criteria
- Must be of legal age according to your country.
- Must have had a history of erectile dysfunction for at least 3 months.
- Must currently and have been using sildenafil for the last six weeks.
- Agree to not use any other ED treatment during the study.
- Anticipate the same female sexual partner for the study.
Exclusion Criteria
- History of other primary sexual disorder
- Treatment with nitrates
- Have a penile implant or clinically significant penile deformity
- History of certain heart problems
- Do not meet certain lab value reference ranges
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 sildenafil Currently prescribed dosage of sildenafil is continued until wash-out period. 2 tadalafil 20 mg tadalafil given after one week sildenafil wash-out period.
- Primary Outcome Measures
Name Time Method Patient choice of treatment (either sildenafil or tadalafil) for use in the extension phase 14 weeks
- Secondary Outcome Measures
Name Time Method Assessment of sexual encounter attributes measured by the PAIRS scale including the Sexual Self-Confidence, Romance, and Time Pressure domains. 26 weeks
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇧🇷Sao Paulo, Brazil